Roche chief executive Thomas Schinecker said today that one in five of the pharma division’s pipeline of new molecular entities (NMEs) has been culled in the last few months as part of a shift ...

On the organic front, the pharma company has a deep pipeline of 113 molecular entities. With 37 candidates in phase three and three in the registration phase, there is visibility for growth as new ...

Bristol Myers Squibb reported strong fourth-quarter earnings but its outlook for 2025 failed to meet expectations.

Q4 2024 Management View CEO Thomas Schinecker emphasized that 2024 was an "excellent year," with overall group sales growing 7%, driven by 9% growth in the base business. Pharma and diagnostics ...

Most entities can be simply and efficiently treated by repeated phlebotomies, provided an early diagnosis has been made. Molecular identification of the various HFEand non-HFEmutations represents ...